Personalized Cell Therapies Market by Cell Type (Hematopoietic Stem Cell, Skeletal Muscle Stem Cell, Mesenchymal Stem Cells, Lymphocytes, Others), By Application (Cardiovascular Disorders, Diabetes, Neurological Disorders, Cancer, Others), and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)    

Personalized Cell Therapies Market size was valued at USD 12,252.24 million in 2021, growing at a CAGR of 23.6% from 2022-28. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policymakers engaged in the manufacturing and supply of personalized cell therapies. Research & Development is evolving, various cell types developed into treatments as novel cell therapies due to its potential applications. Bone marrow transplant or hematopoietic stem cell transplant widely used cell therapy due to the treatment of blood cancer. Increased prevalence of cancer, a rise in research and adoption of advanced technologies are expected attract the demand for the market. Key Development: On August 19, 2016, the European Commission has granted conditional marketing authorization for Zalmoxis, patient-specific adjunctive treatment in haploidentical hematopoietic stem cell transplantation for adults with hematological malignancies.